A complete global analysis of the prospects for markets and companies in this dynamic industry sector
Features and benefits of this thoroughly-researched and highly-regarded management report:
Industry consolidation, new market opportunities, the latest on biosimilars plus much, much more! This leading report, now in its 10th year of publication, draws on primary research with companies, statistics offices, health ministries and trade associations worldwide and provides standard, comparative data and discussion on key issues. This extensive data set is interpreted and evaluated by the editors to provide a complete and compelling review of the whole sector.
Key facts, issues and questions
World Generics per capita spend (US$) forecast to 2016
If the branded pharmaceutical industry was facing a patent cliff it is now teetering on the edge of it. Ironically, it is the world’s best selling drug, Lipitor, which exemplifies the trend. Despite still having patent protection, Pfizer has been unable to stem the tide of interest and pressure from a number of companies, Ranbaxy being chief amongst them. Despite pressure on prices in many markets, the generic sector continues to thrive with increased sales across the board in 2011. The maturity of the sector can also be seen in the size of the businesses: there are now 17 generic companies with revenues in excess of US$1 billion, 5 more than in 2008/09.
Consolidation and collaboration continues to be the game plan for many in the sector. The rationalisation of the industry continues, but it is driven by different motivations. Certainly Teva’s acquisition of ratiopharm was of the traditional model of adding market and value, but the 2011 acquistion of Cephalon is altogether more interesting as it supports Teva’s long term movement to the development of branded drugs. But adding capability is equally important. Watson’s acquisition of Arrow group also provided a stake in Eden Biodesign which gives the company a platform for the biosimilars market.
The generic market is experiencing two opposing trends driven by the global downturn. On one hand, the use of generics is increasing due to their cost-effectiveness and adoption has accelerated in markets where branded prescribing was dominant. On the other hand, the squeeze on government spending has not left generics untouched with many countries lowering generic prices through cuts in reimbursement rates or contract tendering with a resultant squeeze on margins.
All customers get the practical power of Espicom Interactive and at no additional cost! The interactive web-based version of The World Generic Market Report will rapidly identify the information you are looking for.
Espicom’s Generic Drug Business Information; Espicom is the leading provider of business information on the global generic drug and emerging biosimilar markets. Throughout the year we publish a range of titles and reports which bring insight to the trends and developments which are affecting this major pharmaceutical sector. Please click on the title link below for more information.
World Generic Markets
A unique twice-monthly business publication which covers the latest company and market developments and reports on ANDA approvals, litigation, company performance and regulatory developments.
Global Biosimilars: A return to optimism? (January 2012)
Despite some commentators predicting a muted or near nonexistent market for advanced biosimilars, many companies - and some surprising names - are positioning
themselves for market entry.
Biosimilars Business Review
Biosimilar products are entering a new phase in their development but considerable technical and regulatory hurdles remain. Biosimilars Business Review is a quarterly business intelligence service that gets under the skin of this rapidly emerging sector to probe and analyse the issues it faces.
Generic Drugs: Global collaboration opportunities (Dec 2011)
This insightful report from Espicom provides a key resource for the wide assessment of 160 medium-sized generic companies operating in 35 markets worldwide. Identify merger, acquisition and partner candidates in the rapidly changing and challenged global generics market.
Contact email@example.com for details, or visit www.espicom.com/generics